The connective tissue growth factor (CTGF) is responsible for enhancing matrix deposition in cancers, and anti-CTGF therapy can reduce matrix deposition in murine pancreatic cancer model [337]. The gene discussed is CCN2; the disease is familial pancreatic carcinoma.